lobaplatin (D19466) / COSCIENS Biopharma - LARVOL DELTA

Patient Characteristics, Treatment Patterns, and Safety of 1L Osimertinib+Ctx in EGFRm NSCLC: A Prospective, Real-World Study (IASLC-WCLC 2026) - "At the time of DCO (30 November 2025), with a median follow-up duration of 9.1 months (IQR: 5.97, 12.16), Two distinct types of CTx administered in combination with osimertinib were observed, a total of 429 (80.6%) patients received induction therapy, with a median duration of induction CTx of 3.0 months (IQR: 2.2, 3.9), 397(92.5% ) were treated with cisplatin/carboplatin-based CTx regimens plus pemetrexed, and 21(4.9%) received lobaplatin/nedaplatin plus pemetrexed, 246 out of these 429 patients received maintenance CTx, of which 242(98.4%) was pemetrexed. In parallel, a total of 103 (19.4%) patients received only Single-agent CTx regimens including 61 patients of pemetrexed, 34 patients of etoposide, and 8 patients of vinorelbine.The most common TRAE was anemia(51.1%) and Leukopenia(49.7%), and no new safety signals were identified...CTx regimens were diverse in clinical practice; however, the majority consisted of cisplatin/carboplatin plus pemetrexed, no new AEs were..."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Leukopenia • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR

Advanced pulmonary carcinoid managed with chemoimmunotherapy and antiangiogenic agent: A case report and literature review. (PubMed, Mol Clin Oncol) - "However, subsequent radiologic surveillance revealed enlargement of mediastinal lymph nodes, prompting the initiation of a triple-modality systemic regimen comprising lobaplatin, the PD-1 inhibitor sintilimab, and the antiangiogenic agent anlotinib. Although randomized data remain scarce, experience suggests that multimodal systemic therapy may offer disease control in selected patients. Further prospective studies are warranted to refine treatment paradigms for this uncommon malignancy."

Journal • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

A Prospective, Exploratory Study of Retlirafusp Alpha Combined with Chemotherapy as Neoadjuvant Therapy for Patients with Resectable Gastric and Esophagogastric Junction Adenocarcinoma (ChiCTR) - P2 | N=37 | Recruiting | Sponsor: Xijing Hospital, Air Force Medical University; Xijing Hospital, Air Force Medical University

New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • HER-2

Predicting PPOI secondary to laparoscopic radical resection of rectal cancer combined with lobaplatin hyperthermic intraperitoneal chemotherapy: a multi-center study. (PubMed, BMC Surg) - "These predictors and models were able to assess the potential for PPOI following laparoscopic radical curative rectal cancer combined with lobaplatin hyperthermic intraperitoneal chemotherapy. Early alerts can be provided in a clinical setting, helping medical professionals make informed judgments and select the most appropriate treatment strategy (https://zw17786325639.shinyapps.io/ppoi/)."

Journal • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Temperature-sensitive liquid embolic agent loaded with Lobaplatin in the TACE procedure for rabbit VX2 liver tumor. (PubMed, Sci Rep) - "Furthermore, T-TACE down-regulated cyclin B and P53 expression, while up-regulating PD-L1. This study demonstrates that TACE using TempSLE loaded with lobaplatin shows more favorable modulation of proliferation, apoptosis markers, and PD-L1 expression in tumor treatment."

IO biomarker • Journal • Preclinical • Liver Cancer • Oncology • Solid Tumor • BCL2 • HIF1A • PCNA • TP53

Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study. (PubMed, J Gastrointest Oncol) - "While perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) remains the global standard for locally advanced resectable AEG, its substantial hematologic toxicity and perioperative tolerability concerns may limit broader adoption in some Asian patients in real-world clinical practice. This study aimed to assess the perioperative feasibility and safety of neoadjuvant adebrelimab combined with chemotherapy (nab-paclitaxel, lobaplatin, and S-1) in patients with resectable, locally advanced AEG...Neoadjuvant adebrelimab combined with triplet chemotherapy demonstrated acceptable perioperative feasibility, manageable toxicity, and preliminary pathological antitumor activity in patients with locally advanced AEG. Given the exploratory single-arm design and short follow-up, the findings should be considered hypothesis-generating and require validation in larger multicenter randomized trials."

Journal • P2 data • Esophageal Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Oncology • PD-L1

Phase I clinical trial of lobaplatin combined with image-guided volume-modulated arc radiation therapy in locally advanced cervical cancer. (PubMed, BMC Cancer) - P1 | "The MTD of weekly lobaplatin concurrent with VMAT and brachytherapy for LACC was established as 14 mg/m2. A weekly dose of 12 mg/m2 of lobaplatin is recommended in combination with radiotherapy in patients with LACC."

Journal • P1 data • Cervical Cancer • Fatigue • Neutropenia • Solid Tumor • Thrombocytopenia

Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis. (PubMed, Expert Rev Anticancer Ther) - "Twenty-five treatment nodes were formed, with paclitaxel (P) or docetaxel (D) + anthracycline - based (A) chemotherapy as the main comparator. Compared with PA-based + cyclophosphamide, higher pCR rates were observed with PA-based + carboplatin + pembrolizumab + cyclophosphamide (OR 3,04) and PA - based + carboplatin + veliparib + cyclophosphamide (OR 2,67). When DA-based + cyclophosphamide was the comparator, DA-based + cyclophosphamide + bevacizumab (OR 1,67) increased pCR. The SUCRA ranked PA-based + carboplatin + pembrolizumab, paclitaxel + carboplatin + atezolizumab, and DA-based + lobaplatin as most effective. Platinum agents, PARP inhibitors, and immune checkpoint inhibitors were associated with higher pCR rates in early-stage TNBC. CRD42025640277."

Journal • Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Gadolinium-functionalized carbon dot drug delivery systems: Synthesis, properties, dual-mode imaging, and tumor theranostics. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Lobaplatin (LBP) was loaded on Gd-CDs-HA by electrostatic adsorption to construct the drug delivery system (Gd-CDs-HA-LBP)...Bioimaging experiments indicate its excellent targeting cell efficacy and FL/MRI dual-mode imaging capabilities. These results indicate that Gd-CDs-HA-LBP, as an efficient FL/MRI dual-mode imaging probe, holds great potential for application in tumor therapy."

Journal • Oncology

Construction of a Prognostic Model Based on Insulin Resistance-Related Genes to Predict TACE Response and Identification of PD-98059 as a Potential Therapeutic Agent. (PubMed, J Hepatocell Carcinoma) - "Cell experiments confirmed that PD-98059 synergistically enhanced the inhibitory effect of lobaplatin on HCC cell proliferation. The insulin resistance model tailored for TACE effectively predicts patient prognosis. Via the effect of MEK inhibitor PD-98059, the efficacy of TACE in patients can be improved."

Journal • Diabetes • Hepatocellular Cancer • Liver Cancer • Metabolic Disorders • Oncology • Solid Tumor • DUSP9 • SERPINE1

A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing. (PubMed, Gynecol Oncol Rep) - "Observed antitumor activity in this small phase I cohort are exploratory and warrant confirmation in larger, appropriately powered studies. A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Preliminary Safety and Tolerability Supporting Clinical Trial Dosing."

Journal • P1 data • Platinum sensitive • Neutropenia • Ovarian Cancer • Pain • Solid Tumor • Thrombocytopenia

Comprehensive diagnosis and individualized treatment of multiple primary lung cancer: A case report. (PubMed, Exp Ther Med) - "The patient was treated with a two-stage surgery (first surgery on the left lung, second surgery on the right lung) according to the protocol, coupled with adjuvant chemotherapy (700 mg pemetrexed combined with 45 mg lobaplatin) between surgeries. In addition, an individualized treatment design would be more beneficial to patients with MPLC, especially those with a large number of lesions in both lungs. The present study reports a case of the diagnosis and individualized treatment of MPLC with multiple lesions in both lungs, which provides a reference for the diagnosis and treatment of similar patients."

Journal • Lung Cancer • Oncology • Solid Tumor

Influence of gemcitabine combined with lobaplatin interventional embolization on vaginal flora and biofilm formation in patients with advanced cervical cancer. (PubMed, Afr J Reprod Health) - "GEM+LOB interventional embolization not only improved treatment efficacy and survival prognosis in patients with locally advanced cervical cancer but also modulated vaginal microbiota imbalance and inhibited biofilm formation of Gv. These findings provide a new theoretical basis for optimizing clinical treatment strategies for cervical cancer and exploring the relationship between cancer therapy and vaginal microecological balance."

Clinical • Journal • Cervical Cancer • Oncology • Solid Tumor • Vaginal Cancer

Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial. (PubMed, Nat Commun) - "The incidence of late toxic effects is similar between the therapy groups, except for grades 1-2 peripheral neuropathy (p = 0.033), grades 1-2 deafness/otitis (p = 0.021), and grades 1-2/3 nephrotoxicity (p = 0.005; p = 0.021), the incidence of which is greater in the cisplatin-based therapy group than in the lobaplatin-based therapy group. Our findings suggest that lobaplatin and fluorouracil induction chemotherapy plus lobaplatin-based concurrent chemoradiotherapy is an alternative doublet treatment strategy to cisplatin-based concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma."

Journal • P3 data • Nasopharyngeal Carcinoma • Oncology • Otorhinolaryngology • Pain • Solid Tumor

Efficacy and Safety of Iparomlimab and Tuvonralimab Combined with Albumin-bound Paclitaxel and Lobaplatin as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer：A Prospective, Multicenter, Single-Arm Study (ChiCTR) - P4 | N=67 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

New P4 trial • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Safety and efficacy of hyperthermic intraperitoneal chemotherapy of lobaplatin after cytoreductive surgery for appendiceal mucinous neoplasm with PCI>=20: a prospective, single-arm, single-center clinical trial (ChiCTR) - P=N/A | N=47 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University

New trial • Appendix Cancer • Oncology

Malignant mesothelioma in rare sites: two case reports. (PubMed, Front Oncol) - "Conversely, a 66-year-old male with MPM exhibited primary platinum resistance, progressing after first-line pemetrexed/lobaplatin and subsequent second-line chemotherapy. Peritoneal mesothelioma responded better to immuno-chemotherapy, while MPM showed platinum resistance. These contrasting disparate outcomes underscore that precise pathology and individualized treatment based on anatomic site are crucial, suggesting that malignant pleural and peritoneal mesothelioma may represent distinct clinical entities."

Journal • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Peritoneal Mesothelioma • Pleural Mesothelioma • Solid Tumor

Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. (PubMed, J Gynecol Oncol) - "Lobaplatin-based CCRT demonstrates comparable efficacy to cisplatin in elderly cervical cancer patients, with superior renal safety and improved gastrointestinal tolerability, establishing it as a viable alternative for cisplatin-intolerant populations."

Journal • P2 data • Cervical Cancer • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

Real-world survival patterns and multimodal therapy utilization in small cell lung cancer: a retrospective cohort study in a Chinese countryside hospital. (PubMed, Front Oncol) - "Of 132 patients (64 LS-SCLC, 68 ES-SCLC), most received first-line platinum-etoposide regimens, with diminishing treatment continuity in later lines due to cumulative toxicities. Conversely, irinotecan-lobaplatin combinations provided limited benefit. Findings emphasize the need for personalized treatment sequencing and improved access to standardized multimodal care in rural healthcare settings."

Journal • Real-world evidence • Retrospective data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Pathological complete response to conversion therapy for lung adenocarcinoma with brain metastasis: a case report. (PubMed, Front Oncol) - "After multidisciplinary discussion, it was decided to administer targeted therapy with furmonertinib, chemotherapy with pemetrexed and lobaplatin, and immunotherapy with tislelizumab. For patients with metastatic advanced NSCLC, systemic treatment involving chemotherapy plus immunotherapy and targeted therapy is expected to become one of the options. Moreover, it is likely to achieve successful conversion surgery and further efficacy after combined therapy."

IO biomarker • Journal • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MAP2K1 • MAPK1 • PD-L1

Pt-seq unveils the genomic binding pattern of platinum-based drugs. (PubMed, Sci Adv) - "By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatin-DNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt-DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs."

Journal • Oncology

The Efficacy and Safety of Lobaplatin vs. Cisplatin in Concurrent Chemoradiotherapy for Elderly Patients with Cervical Cancer: An Open-Label,Prospective Phase 2 Study (ASTRO 2025) - "Compared with cisplatin, lobaplatin has similar efficacy in the treatment of concurrent chemoradiotherapy for elderly patients with cervical cancer, with tolerable adverse reactions and lower upper gastrointestinal reaction and renal toxicity. It can be clinically recommended for elderly patients with cervical cancer who have renal insufficiency or intolerable gastrointestinal reactions."

Clinical • P2 data • Cervical Cancer • Oncology • Solid Tumor

Albumin-bound paclitaxel combined with lobaplatin using different administration methods in the treatment of cervical cancer: Study on the efficacy and its effect on immune function and inflammatory response. (PubMed, Pak J Med Sci) - "Albumin-bound paclitaxel combined with lobaplatin has a significant therapeutic effect for interventional chemoembolization of patients with cervical cancer. It may significantly improve the short-term and long-term clinical efficacy and immune function, and alleviate the inflammatory condition of cervical cancer patients."

Journal • Cervical Cancer • Oncology • Solid Tumor • IFNG • IL10 • TGFB1 • TNFA

Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. (PubMed, Discov Oncol) - "Platinum-based anthracycline-free NAC regimens combined with taxanes appear to be both effective and well-tolerated in patients with TNBC. Nevertheless, in the absence of randomized controlled trials (RCTs) directly comparing this approach to anthracycline-based regimens, further investigation is warranted to substantiate these findings."

Journal • Retrospective data • Breast Cancer • Leukopenia • Neutropenia • Solid Tumor • Triple Negative Breast Cancer

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer (clinicaltrials.gov) - P4 | N=468 | Not yet recruiting | Sponsor: Shandong Cancer Hospital and Institute

New P4 trial • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor